Frontiers in oncology · 2025
A case report focusing on diagnosis and intervention of chronic myeloid leukemia in blast crisis (acute megakaryoblastic leukemia subtype).
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Long, Xiao Yang, Cui Na, Zhang Liping, Wang Lijing, Gao Cheng, Shi Jingfei, Yuan Changyong, Cui Chao
Аннотация
OBJECTIVES: To report a chronic myeloid leukemia (CML) blast crisis case, accurately diagnose its subtype, explore suitable treatment considering patient factors, and emphasize multidisciplinary diagnosis importance.
METHODS: Diagnosis relied on multiple approaches: bone marrow morphology, immunophenotyping, chromosomal karyotype analysis, and fusion gene detection to identify the subtype of CML blast crisis. Given the patient's financial constraints and drug availability, the third - generation tyrosine kinase inhibitor (TKI) orelabatinib was chosen for treatment. Minimal residual disease (MRD) was rechecked two weeks after initiating therapy to assess treatment efficacy.
RESULTS: The patient was diagnosed with CML blast crisis of the acute megakaryoblastic leukemia subtype (M7), presenting with BCR/ABL1 fusion gene positivity, complex karyotypic abnormalities, and secondary myelofibrosis. After two weeks of orelabatinib treatment, MRD levels significantly declined, demonstrating the therapy's effectiveness.
DISCUSSION: This case underscores the necessity of multidisciplinary collaboration for accurate diagnosis. Treatment selection for rare subtypes like M7 requires balancing medical need with patient - specific factors. The successful reduction in MRD validates the rationality of orelabatinib use, yet more research on treatment options for rare subtypes is warranted.
CONCLUSION: Multidisciplinary methods are crucial for diagnosing CML blast crisis. Orelabatinib shows efficacy, and more research on personalized treatment is needed.
METHODS: Diagnosis relied on multiple approaches: bone marrow morphology, immunophenotyping, chromosomal karyotype analysis, and fusion gene detection to identify the subtype of CML blast crisis. Given the patient's financial constraints and drug availability, the third - generation tyrosine kinase inhibitor (TKI) orelabatinib was chosen for treatment. Minimal residual disease (MRD) was rechecked two weeks after initiating therapy to assess treatment efficacy.
RESULTS: The patient was diagnosed with CML blast crisis of the acute megakaryoblastic leukemia subtype (M7), presenting with BCR/ABL1 fusion gene positivity, complex karyotypic abnormalities, and secondary myelofibrosis. After two weeks of orelabatinib treatment, MRD levels significantly declined, demonstrating the therapy's effectiveness.
DISCUSSION: This case underscores the necessity of multidisciplinary collaboration for accurate diagnosis. Treatment selection for rare subtypes like M7 requires balancing medical need with patient - specific factors. The successful reduction in MRD validates the rationality of orelabatinib use, yet more research on treatment options for rare subtypes is warranted.
CONCLUSION: Multidisciplinary methods are crucial for diagnosing CML blast crisis. Orelabatinib shows efficacy, and more research on personalized treatment is needed.